What is the main purpose of this 8-K filing?

The main purpose of this 8-K filing is to officially announce AbbVie Inc.'s financial results for the third quarter ended September 30, 2021. It serves to make the press release containing these results publicly available and filed with the SEC.

Where can I find the detailed financial results for Q3 2021?

The detailed financial results for the third quarter of 2021 can be found in the press release dated October 29, 2021, which is furnished as Exhibit 99.1 to this 8-K filing and incorporated by reference.

What specific financial information should I look for in the press release?

Investors should look for key financial metrics such as total revenue, revenue breakdown by product and geography, earnings per share (EPS), net income, operating expenses, and any forward-looking financial guidance or outlook provided by AbbVie's management for future periods.

Does this 8-K filing contain any new business initiatives or significant legal updates?

This specific 8-K filing, based on the provided details, primarily focuses on the announcement of financial results. While the accompanying press release might offer some commentary on business performance and outlook, significant new business initiatives or legal updates are typically disclosed in separate 8-K filings under different item numbers (e.g., Item 1.01 for material agreements or Item 8.01 for other material events).

ABBV 8-K: Earnings & Results

Summary

AbbVie Inc. (ABBV) filed an 8-K on October 29, 2021, to report its financial results for the third quarter ended September 30, 2021. The primary purpose of this filing is to provide investors with the official announcement of the company's performance during the quarter, as detailed in the accompanying press release furnished as Exhibit 99.1. Investors should refer to this press release for specific financial metrics, revenue figures, earnings per share, and any forward-looking guidance provided by the company. While the 8-K itself is brief and primarily serves as a vehicle to disseminate the press release, the contained information is critical for assessing AbbVie's operational success, growth trajectory, and overall financial health. Key details regarding the performance of core products, such as Humira and Skyrizi/Rinvoq, as well as any updates on strategic initiatives or regulatory developments, would be found within the furnished press release. Investors should analyze these results in the context of market expectations and the broader pharmaceutical industry landscape.

Key Highlights

1AbbVie Inc. announced its financial results for the third quarter ended September 30, 2021, via an 8-K filing on October 29, 2021.
2The 8-K filing incorporates by reference a press release (Exhibit 99.1) containing the detailed financial results and operational performance.
3Investors are directed to the furnished press release for specific financial data, including revenue, earnings per share, and any updated guidance.
4This filing serves as the official notification of AbbVie's Q3 2021 performance to the market.
5The report includes the standard cover page formatted in Inline XBRL (Exhibit 101).

AbbVie Inc. 8-K Report, Financial Results (Oct 29, 2021)

Summary

Key Highlights

Frequently Asked Questions